Shanghai Shen Lian Biomedical Past Earnings Performance
Past criteria checks 0/6
Shanghai Shen Lian Biomedical's earnings have been declining at an average annual rate of -34.4%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 1.2% per year.
Key information
-34.4%
Earnings growth rate
-35.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 1.2% |
| Return on equity | -1.6% |
| Net Margin | -6.4% |
| Last Earnings Update | 30 Sep 2024 |
Revenue & Expenses Breakdown
How Shanghai Shen Lian Biomedical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 310 | -20 | 167 | 52 |
| 30 Jun 24 | 305 | -13 | 163 | 51 |
| 31 Mar 24 | 308 | 13 | 149 | 48 |
| 31 Dec 23 | 301 | 32 | 138 | 45 |
| 30 Sep 23 | 281 | 26 | 131 | 43 |
| 30 Jun 23 | 313 | 48 | 135 | 42 |
| 31 Mar 23 | 321 | 53 | 135 | 43 |
| 31 Dec 22 | 329 | 61 | 137 | 39 |
| 30 Sep 22 | 373 | 91 | 135 | 43 |
| 30 Jun 22 | 344 | 89 | 120 | 36 |
| 31 Mar 22 | 365 | 106 | 123 | 35 |
| 31 Dec 21 | 358 | 110 | 123 | 35 |
| 30 Sep 21 | 308 | 84 | 130 | 28 |
| 30 Jun 21 | 336 | 113 | 133 | 32 |
| 31 Mar 21 | 322 | 111 | 131 | 30 |
| 31 Dec 20 | 338 | 130 | 123 | 32 |
| 30 Sep 20 | 330 | 138 | 113 | 30 |
| 30 Jun 20 | 278 | 100 | 108 | 29 |
| 31 Mar 20 | 257 | 90 | 100 | 28 |
| 31 Dec 19 | 254 | 78 | 106 | 27 |
| 31 Dec 18 | 275 | 88 | 105 | 21 |
| 31 Dec 17 | 302 | 99 | 117 | 17 |
| 30 Jun 17 | 283 | 89 | 129 | 0 |
| 31 Mar 17 | 276 | 81 | 125 | 0 |
| 31 Dec 16 | 268 | 73 | 104 | 17 |
| 31 Dec 15 | 241 | 76 | 103 | 0 |
| 31 Dec 14 | 204 | 61 | 93 | 0 |
| 31 Dec 13 | 193 | 42 | 104 | 0 |
Quality Earnings: 688098 is currently unprofitable.
Growing Profit Margin: 688098 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688098 is unprofitable, and losses have increased over the past 5 years at a rate of 34.4% per year.
Accelerating Growth: Unable to compare 688098's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 688098 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.5%).
Return on Equity
High ROE: 688098 has a negative Return on Equity (-1.6%), as it is currently unprofitable.